This website allows the public to search and find relevant clinical trials. It is also for approved external groups to reconnect to the ANZCTR’s API.


Registration, updating trial details and changing user account details are not yet available.


If you are concerned about obtaining a prospective registration label for your trial on time, we recommend registering your trial on ClinicalTrials.gov or your closest WHO-recognised Primary Registry (see https://www.who.int/clinical-trials-registry-platform/network/primary-registries).


We apologise for this disruption. As soon as we know when registering and updating trials will become available, this information will be listed on this website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12612001211853
Ethics application status
Yes
Date submitted
2/11/2012
Date registered
15/11/2012
Date last updated
Type of registration
Retrospectively registered

Titles & IDs
Public title
TROG 11.03 A Randomised Phase III Trial of High Dose Palliative Radiotherapy (HDPRT) Versus Concurrent Chemotherapy + HDPRT (C-HDPRT) in Patients with Good Performance Status, Locally Advanced/Small Volume Metastatic Non Small Cell Lung Cancer (NSCLC) Not Suitable for Radical Chemo-Radiotherapy (P_LUNG GP)
Scientific title
TROG 11.03 A Randomised Phase III Trial of High Dose Palliative Radiotherapy (HDPRT) Versus Concurrent Chemotherapy + HDPRT (C-HDPRT) in Patients with Good Performance Status, Locally Advanced/Small Volume Metastatic Non Small Cell Lung Cancer (NSCLC) Not Suitable for Radical Chemo-Radiotherapy (P_LUNG GP)
Secondary ID [1] 281485 0
Nil
Universal Trial Number (UTN)
Trial acronym
P_LUNG GP
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non Small Cell Lung Cancer (NSCLC) 287748 0
Condition category
Condition code
Cancer 288089 288089 0 0
Lung - Non small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Chemotherapy + High Dose palliative Radiation Therapy (C-HDPRT)
1. Radiation Therapy; 40Gy/20f (2Gy/f, 4-5f/week)
2. Chemotherapy; IV cisplatin 20mg/m2 (days 1, 8, 15, 22 of RT) plus IV vinorelbine 25mg/m2 (days 1, 8 and 22 of RT).
Intervention code [1] 285992 0
Treatment: Other
Intervention code [2] 285993 0
Treatment: drugs
Comparator / control treatment
High Dose palliative Radiation Therapy (HDPRT) alone

1. Radiation Therapy; 36Gy/12f (3Gy/f, 4-5f/week)
Control group
Active

Outcomes
Primary outcome [1] 288296 0
The primary outcome of this trial is to compare high dose palliative radiotherapy (HDPRT) versus concurrent chemotherapy and HDPRT (C-HDPRT), with respect to the relief of dyspnoea, cough, haemoptysis and chest pain as assessed by change in total symptom burden from baseline to six weeks after the completion of treatment, and the response for each component symptom separately (dyspnoea, cough, haemoptysis, chest pain)
Timepoint [1] 288296 0
Toxicity assesments (NCIC CTCAE v 3.0) and physical exams performed at pre registration, pre treatemnt, during treatment, end of treatment, 2 wks post treatment, 6 weeks post treatment.
Secondary outcome [1] 299777 0
Comparison of the two regimens in terms of dysphagia during treatment by clinical examination and patient reported outcomes.
Timepoint [1] 299777 0
Pre registration, pre treatment, during treatment, end of treatment, 2 wks post treatment, 6 weeks post treatment, 3 months post treatment, 6 months post treatment and then 3 monthly until progression.
Secondary outcome [2] 299869 0
Comparison of the two regimens in terms of thoracic symptom response rate by clinical examination and patient reported outcomes
Timepoint [2] 299869 0
Pre registration, pre treatment, during treatment, end of treatment, 2 wks post treatment, 6 weeks post treatment, 3 months post treatment, 6 months post treatment and then 3 monthly until progression.
Secondary outcome [3] 299870 0
Comparison of the two regimens in terms of duration of thoracic symptom response by clinical examination and patient reported outcomes.
Timepoint [3] 299870 0
Pre registration, pre treatment, during treatment, end of treatment, 2 wks post treatment, 6 weeks post treatment, 3 months post treatment, 6 months post treatment and then 3 monthly until progression.
Secondary outcome [4] 299871 0
Comparison of the two regimens in terms of Quality of Life (QOL) Questionniares (QLQ-C30, QLQ-LC13) and Physician rated Spitzer index
Timepoint [4] 299871 0
Pre registration, pre treatment, during treatment, end of treatment, 2 wks post treatment, 6 weeks post treatment, 3 months post treatment, 6 months post treatment and then 3 monthly until progression.
Secondary outcome [5] 299872 0
Comparison of the two regimens in terms of Toxicity (NCIC CTCAE v 3.0)
Timepoint [5] 299872 0
Toxicity assesments (NCIC CTCAE v 3.0) at Pre treatment, during treatment, end of treatment, 2 wks post treatment, 6 weeks post treatment, 3 months post treatment, 6 months post treatment and then 3 monthly until progression.
Secondary outcome [6] 299873 0
Comparison of the two regimens in terms of Progression-free survival by physical exams and imaging.
Timepoint [6] 299873 0
Physical Examinations; pre registration, pre treatment, during treatment, end of treatment, 2 wks post treatment, 6 weeks post treatment, 3 months post treatment, 6 months post treatment and then 3 monthly until progression. Medical Imaging (CT scans +/-PET); Pre regisatration, 6 weeks post treatment, 3 months post treatment and then 3 monthly until progression (if clinically indicated).
Secondary outcome [7] 299874 0
Overall survival (clincal assessments)
Timepoint [7] 299874 0
Pre treatemnt, during treatment, end of treatment, 2 wks post treatment, 6 weeks post treatment, 3 months post treatment, 6 months post treatment and then 3 monthly until progression.

Eligibility
Key inclusion criteria
1. Aged 18 years or older
2. ECOG PS 0-1,
3. Histological or cytological proven stage III or IV NSCLC of any subtype: Adenocarcinoma, Squamous Cell Carcinoma (SCC), NSCLC Not Otherwise Specified (NOS) or Other (including Large Cell Undifferentiated).
4. Symptoms due to intrathoracic disease (at least one of cough, dyspnoea, haemoptysis, chest pain),
5. Patients with Stage III NSCLC not suitable for radical chemo-radiotherapy (due to concurrent medical illness, weight loss > 10% or tumour volume too large for radical radiation fields (e.g. dose constraints for organs at risk cannot be met using radical radiation fields or at the discretion of the investigator) or patients with locally advanced thoracic disease and a FDG-PET detected solitary metastasis (small volume Stage IV disease), Not cerebral metastasis
6. Planned for HDPRT to achieve local control
7. Adequate organ function;
a) Bone marrow: Haemoglobin (Hb) >/= 100g/l, Absolute neutrophil count (ANC) >/= 1.5 , Platelet count >/= 100
b) Hepatic: Serum bilirubin </= 1.0 x upper limit of normal (ULN), AST/ALT </= 2.0 x ULN, ALP </= 2.5 x ULN.

c) Renal: Creatinine Clearance >/= 55 ml/min
8. No prior therapy for NSCLC
9. Able to commence Radiotherapy no later than 6 weeks, but preferably within 4 weeks from the time of participant randomisation. It is preferred that RT be commenced on a Monday or Tuesday.
10. Has provided written informed consent to participate in this trial
11. Participants capable of childbearing are using adequate contraception
12. Available for follow-up for a minimum of 3 months.
Minimum age
18 Years
Maximum age
100 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Receiving treatment with another investigational agent
2. History of any other cancer (except non-melanomatous skin cancer or carcinoma in situ of the cervix) unless in complete remission and off all therapy for that cancer for at least 3 years.
3. Women who are pregnant or lactating
4. Previous radiotherapy to the area to be treated, at any time.
5. Significant medical conditions which in the opinion of the investigator would compromise the planned delivery of the chemotherapy and radiotherapy or which may be potentially exacerbated by these modalities

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Patients will be randomised in the ratio of 1:1 between the two arms, HDPRT and C-HDPRT. Allocation is determined by central randomisation by computer and allocation concealment is used.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Allocation to treatment arms will be stratified by tumour stage (III, IV), tumour histology (adenocarcinoma, SCC, other), major chest symptoms (presence or absence of each of dyspnoea, cough, haemoptysis and chest pain) and treating Institution, using the minimisation technique (with a random component).
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Open to recruitment
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment outside Australia
Country [1] 292077 0
State/province [1] 292077 0

Funding & Sponsors
Funding source category [1] 286258 0
Charities/Societies/Foundations
Name [1] 286258 0
Cancer Australia
Country [1] 286258 0
Australia
Primary sponsor type
Other Collaborative groups
Name
Trans Tasman Radiation Oncology Group
Address
Central Operations Office
Department of Radiation Oncology
Calvary Mater Newcastle
Locked Bag 7
Hunter Region Mail Centre
NSW 2310
Country
Australia
Secondary sponsor category [1] 285058 0
None
Name [1] 285058 0
Address [1] 285058 0
Country [1] 285058 0
Other collaborator category [1] 277151 0
Other Collaborative groups
Name [1] 277151 0
Australasian Lung Trials Group
Address [1] 277151 0
ALTG Group Manager The Australian Lung Foundation 44 Brookes Street Bowen Hills, QLD 4006
Country [1] 277151 0
Australia

Ethics approval
Ethics application status
Yes
Ethics committee name [1] 288335 0
Metro South Hospital and Health Service Human Research Ethics Committee (EC00167)
Ethics committee address [1] 288335 0
Ethics committee country [1] 288335 0
Australia
Date submitted for ethics approval [1] 288335 0
01/05/2012
Approval date [1] 288335 0
28/06/2012
Ethics approval number [1] 288335 0
HREC/12/QPAH/172

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Contact person for public queries
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided
Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.